Lack of Interaction between Amiodarone and Mexiletine in Cardiac Arrhythmia Patients

• Published in: Journal of clinical pharmacology 2002-03, Vol.42 (3), p.342-346
• Main Authors: Yonezawa, Emi, Matsumoto, Kana, Ueno, Kazuyuki, Tachibana, Miho, Hashimoto, Hiroshi, Komamura, Kazuo, Kamakura, Shiro, Miyatake, Kunio, Tanaka, Kazuhiko
• Format: Article
• Language: English
• ISSN: 0091-2700
• DOI: 10.1177/009127000204200312

Amiodarone has pharmacokinetic interactions with various therapeutic agents, including phenytoin, flecainide, and cyclosporine. Mexiletine is metabolized by CYP2D6 and CYP1A2. The objective of this study is to evaluate the effect of amiodarone on the pharmacokinetics of mexiletine through its inhibition of various cytochrome P450 (CYP) subtypes. In a series of 181 inpatients with supraventricular tachyarrhythmias, 26 inpatients received mexiletine and amiodarone therapy (MEX + AMD group), and the others received mexiletine therapy (MEX group). In 10 inpatients of the MEX + AMD group, the mexiletine clearance (CL sub(MEX)/F) before and after coadministration of amiodarone was compared. CL sub(MEX)/F was also compared in the MEX and MEX + AMD groups after the start of amiodarone therapy. Serum mexiletine, amiodarone, and desethylamiodarone concentrations were measured by an HPLC method. The CL sub(MEX)/F was estimated by the Bayesian method using population pharmacokinetic analysis. There was no significant difference in CL sub(MEX)/F before and after 1-month coadministration of amiodarone in 10 inpatients of the MEX + AMD group. Although serum amiodarone and desethylamiodarone concentrations gradually increased with time after the start of amiodarone therapy in these patients, CL sub(MEX)/F showed no change at 3 and 5 months after the start of amiodarone therapy. There was no significant difference in CL sub(MEX)/F of the MEX group and the MEX + AMD group. The results suggest that the pharmacokinetics of mexiletine is not affected by amiodarone in patients with cardiac arrhythmias.